Friday, March 29, 2024
Olympus, a leading global medical technology company specializing in innovative solutions for medical and surgical procedures, has announced a significant achievement regarding its iTind™ device. This milestone entails expanded patient access through inclusion in major healthcare group purchasing organization (GPO) contracts across the United States. The iTind procedure offers a minimally invasive approach for treating benign prostatic hyperplasia (BPH), providing patients with an effective alternative to medications, permanent implants, or tissue removal.
BPH is a prevalent health issue affecting men over 50, characterized by symptoms such as frequent urination, weak urinary stream, and nocturia. The iTind procedure has emerged as a promising solution, offering relief without compromising sexual function or urinary continence, and avoiding the need for traditional surgical interventions.
This procedure involves the temporary placement of a nitinol device within the prostatic urethra, reshaping it without conventional surgical techniques. Recent data highlights its effectiveness, with patients experiencing sustained relief for over four years post-treatment. Additionally, its inclusion in the American Urological Association (AUA) clinical practice guideline underscores its efficacy, positioning it as a recommended approach for managing BPH-related lower urinary tract symptoms.
The iTind procedure's categorization under Temporary Implanted Prostatic Devices (TIPD) reflects its recognition within the medical community, based on expert consensus and research-backed recommendations. This achievement not only signifies improved accessibility for physicians and patients but also heralds a new era in minimally invasive urological interventions, offering individuals a proven alternative for addressing BPH-related challenges.
Source: prnewswire.com
